title: microRNA-210 as a prognostic factor in patients with breast cancer: meta-analysis.
abstract: BACKGROUND
  microRNA-210 expression in breast carcinoma represents an appealing prognostic tool, but no consensus exists on this debating topic.
  
  
  OBJECTIVE
  We conducted this comprehensive meta-analysis to summarize evidence for use of microRNA-210 to predict patients' clinical outcomes.
  
  
  METHODS
  Relevant literatures were identified using Pubmed and EMBASE. Patients' clinical characteristics and survival related data were extracted. Statistics extracted from Kaplan-Meier survival curves were calculated with methods developed by Parmar, Williamson, and Tierney, multivariate Cox hazard regression analysis data were used directly in Revman 5.0. Pooled hazard ratios (HRs) were calculated to evaluate the prognostic role of microRNA-210.
  
  
  RESULTS
  Finally, 7 studies containing 822 patients were considered eligible, pooled HR (95% CI) of studies for overall survival was 3.94 (1.90-8.15), for disease/recurrence free survival was 3.47 (2.63-4.60) and for metastasis free survival was 2.70 (1.46-5.00). We then respectively grouped the meta-analysis by patients' region (Asia and non-Asia), tumor estrogen receptor/ progesterone receptor/Her-2 expression status (positive or negative) and treatment strategy (preoperative systemic treatment or only surgery). All the subgroup analysis showed stable prognostic value.
  
  
  CONCLUSIONS
  Over-expressed microRNA-210 demonstrated a significantly higher risk of recurrence, metastasis and overall decreased survival rates for breast cancer patients.
authors.affiliation: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
authors.forename: Xuelei
authors.initials: X
authors.lastname: Ma
authors.affiliation: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
authors.forename: Jingyi
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
authors.forename: Binglan
authors.initials: B
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Jing
authors.affiliation: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Liu
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: C543800:MIRN210 microRNA, human; D035683:MicroRNAs
keywords: breast cancer; meta-analysis; microRNA-210; prognostic factor